to Thank the all for I'm thank morning of for and XXXX. of you, fourth you and Lucinda, joining to you good review our quarter pleased us. progress
would Slide to on provide an our like X, programs. First I update in
into on peaks more our post last programs COVID and We period have stable initial entered year, remain now track.
We have not further seen in quarter disruption fourth year. any the last
analysis, work support for and data continue availability to and hard order our samples well centers leukapheresis, logistics as ensure final timely and of short, our teams, products integrity. our with and continental supply trials clinical and chain clinical deliveries transatlantic We as to in to in timely
XXXX. continue December in The program, Phase as now study XXXX. We also track carefully with to provided June can of particular from X pivotal refer on we also very indeed in expected In full FELIX data and ALLCAR AUTOX safety. updates which in remains ASH with AUTOX-ALX, EHA data year, patient and a QX focus on to our the at monitor developments at we the
last We later. a EHA year. at ALEXANDER provided AUTOX, also little will in the and also update DLBCL on an AUTOX of touch study from I ASH at
we AUTOXNG the forward focus guided renewed published to academic And X moving we're a AUTOX data outlook In into Translational looking partners In on program. study the addition, a our January this of business development. we on clinical Science Journal year, AUTOX Phase in provided Medicine. from where
As DLBCL partner program, AUTOX. our to our intention part outlook, this of we announced
our balance net net proceeds. ATM sheet January million in raising XXXX, in proceeds February million approximately and $XXX will next ADSs also More of strengthened our updates ADSs offering under facility public approximately and the of for of detailed we Finally, follow with slide. $XX the sale on
onto on which leukemia, is medical The in acute need the unmet also program relapsed/refractory our is addressing So underserved options moving CNS relapsed/refractory, data study ability unique to in in with population adult X, AUTOX high focusing primary indications development. of FELIX designed expected a year Slide AUTOX. in area lymphoma. the treatment address we're profile lymphoblastic building B-NHL truly the next limited with and on its We're exploring
is addition, next-generation in explored In pediatric the AUTOX/XX being program, patients.
We XXXX. updates in of expect data for these the fourth quarter programs
lymphoma from academic clinical partners. AUTOX in data cell B-cell fourth forward collaboration programs we into data clinical quarter, moving our in our T in the next-generation peripheral malignancies, in with Beyond expect development then and
when with a to that long-term less the than Once followed off long-term transplant a receive cell year. patients median to at this point benefit Slide XX% The in is chemotherapy this relapse. may allogeneic cell lead blinatumomab, patients that XX% fitted while life we I important is our relapsed, in think understand ALL, redirected approved by relapsing therapy or focusing therapy proportion of approved those program cell small adult they're to indication, not no a Moving on it's or X, The CAR is have for achieving Patients with other stem relapsed expectancy T targeted will of T do only benefit. very to with drug is there also stem very antibody patients intense of one inotuzumab, additional Frontline chemotherapy, respond is transplant survival terms CDXX-targeting dose a post-transplant in on therapy however, – intense patients initial the challenge, high therapy. based The chemotherapy of conjugate. And blinatumomab. inotuzumab. patients Most regimens. only therapies, eligible majority or short receive a that of an very Blincyto high-dose time.
This the treating for off However, of high consequence this chemotherapy. immunosuppressive at stage their challenging is from both none courses and of multiple their dose, of these these disease. typically underlying therapies as the At a of toxic drive are and long-term quite very in poor nature a that condition, situation patients very of patients physicians. the stage, benefit disease
lot a medical cause consequence, highly sepsis of As them lot and The U.S., the Japan, of die and very in patients adult death. options infection, development. need primary EU patients of in a X,XXX do high with to new or these the unmet of a relapsed/refractory and core of are as approximately patients prone limited therapeutic
curative are relapsed/refractory responses which safety, product like door ALL number necessitates ALL. Turning a to AUTOX. need significant the adult opening initial relapse patients can intent. innovation therefore illustrate diagnosed in the ALL, X, despite unmet a and journey improved durability, common high in Unlike Slide and with we've funnel adult for to together pulled new for rates ALL, The adult treatment pediatric offer
capture last-line lines look receiving and therapy. patients been some these the target additionally to X,XXX data also drive will into standard-of-care expect move patients of The initial the agents. post but prior patients we exposed in or inotuzumab indication having to approximately to interest We setting to expect those represents to earlier will blina program
underlying Slide condition cells patients like also summarize On the adult T who and ALL. the features successful overall prior are X, leukemic the poor as involve stem key proliferative disease fast almost CAR a of cell proliferating The their potential disease cell challenges toxicity very with we in consequence next number of basic a of treatments. in therapy for
the tolerability of the So very specific combined T profile. minimizing of the a is leukemic product solution good for and product, technical needs molecular leukemic manageable with it's engagement sustained rate transient and while result response its is a but with maximizing and levels high The CAR and to activity survival activity high neurotoxicity. event-free combine the cells, highly persistence profile. cytokine The safety release AUTOX a
remission Moving was XX long-term proportion past in to patients conducting T transplant and XX showed XX%. at of XX drive patients persistent CAR the can and in of molecular in at patients. remissions a at a that us first would sustained highlight of months study hope second XX.X XX, We're Overall, a months data the ASH. key FELIX to complete gives program we confirm months to results. profile December these event-free the median months Slide This lot of The some six survival we cells. receiving a without like now follow-up of with the presented
On looking patients typically the be blinatumomab number XX, for used treatment is may standard-of-care. The therapy. as a primary the the option perspective put the in data inotuzumab to of while AUTOX we're next Slide bridging
clinical safety very this a registrational to the put, blinatumomab, either for prior it on important is compared believe AUTOX realize a comparable blinatumomab before move patients of that AUTOX AUTOX inotuzumab data the we're to good potential profile. that the of blinatumomab, survival exceeding those data of When simple as We and the are as failed six received data, study. If level which a Despite to elevated blinatumomab, twice therapies XX% months And the active looking where comparable. survival, twice event-free months We trial. cytokine syndrome activity the compared approximately a of release are the we're at six least XX% see with In months. you way even is seeing a we look has value with at current care substantial very of prior of for neurotoxicity program AUTOX. at at looking AUTOX, a entering at XX%. blinatumomab the at product to or is XX standard to the that activity and value very had foundation event-free into just
XX, looking inotuzumab. from the to view but Besponsa Slide or key are another and or space, programs commercial in just quick perspective. the at a Blincyto Moving that of two and blinatumomab on approved products We're
the the sales As two were understand in to fourth average you annual the segment with key was the U.S. that Typically of of product and accelerating patients patients its centers cycles Note can commercial of the quarter majority in beyond expansion X,XXX adults. to driver million. academic see, transplant community translates an the which product, for started receiving treated sales product into the this product the patients initial journey. which globally. has hospitals are XXXX XXX approximately reached Blincyto receive the of We
is Both establish DLBCL product moving bode for developments expect properties we product to those [indiscernible] centers, non-academic of key ALL of in Blincyto launch a the also well with centers. While in AUTOX. in experience the to
to turn XX. now Let's Slide
The First primary the pivotal Xb/X with a relapsed/refractory the in It this endpoint motion complete is patients at off, response FELIX XXX disease. approximately Phase is programs rate. in with study overall single-arm obviously study. point is AUTOX
Secondary endpoints of event-free we'll through course as ongoing response. this responses duration of survival include recruit This program molecular is and well the and year. as
also includes explore lymphomas of population. we're ALL studies indolent mentioned, I've That As adult some to and AUTOX clinical in conducting additional the CLL. activity
driven ALL, neglected we its version next-generation minimizing of As expanding a for CDXX exploring in own the loss. presentation cell typically highly also is properties Data additional mentioned planned relapse an antigen patients, AUTOX/XX lymphoma, XXXX. novel, a program rate summary, builds adult in primary the indication. also pediatric looks called a an is there's build non-Hodgkin's anchored In CDXX and also earlier, QX both in and and which started significant lymphoma AUTOX we AUTOX pediatric by indications. at in opportunity a activity active the CNS commercial we're that antigen franchise program The ALL, AUTOX December, In add believe to unique chimeric and B receptor. is into with
partner outpatient patients and setting, tested outpatient the discharged risk we were and Turning administered regimens with next XX, ESMO high We're building due with the the AUTOX of program in profile, concerns in in admitted Patients to in Two commercial for lymphoma. ASH safety clinical ASCO, what of The well-managed, was fever activity broad a XX% year. the believe to the to has level at be moving large to cell Slide potential shown outpatient setting setting. need B all updates serve a care. to diffuse EHA, of manageable shown the safe infection, AUTOX tested program intensive feasibility. cleared. ALEXANDER oral and to we the without We and study Of on profile. best-in-class is last of were footprint program, and considering paired presentations favorable very pembrolizumab provided required were a after safety all demonstrated our were planning
lymphoma for clinical Slide understanding the turn to the let's a product this prepared is profile the expect of year the have need is cell T they with of at a an options our and the currently update expect active in very and So AUTOX good the of lymphoma for medical program, clinical cell end. end XX, AUTOX a of The patients relapse T end towards IND by clinic, program we once after to available treatment XXXX. sister frontline high The therapy. in is limited
XX. particularly to the Moving some programs, will it I relates technology all generation recall, the Autolus, looking suite We're of we XXXX be are which programs, into first of tumor Slide you to toolkit like developed as you showcased of would next to with the and XXXX. XXXX, we've which excited programs to at remind clinics AACR including move to in solid progressing. our several into at very
Our degree hostile cells provide activity designed cell the with strengthening cells to resilience programming to environment cancer modules while against cells withstand cancer high Slide defend T off T T are and attach. specificity the of a create XX. cell cells,
alongside we start have dates. the see can X programs expected You Phase these tabulated next-gen
As of year. QX we AUTOX/XX trial in discussed, ALL note, you clinical will started as and pediatric the last
prostate neuroblastoma year, AUTOX in second initially to cancer study We to move with move of into GDX XXXX we attempt myeloma. All solid a will year. in next tumors to is then this partners. positive haven't our yet AUTOXNG, multiple the the AUTOX academic first particularly half finally, mentioned, collaboration of explored of of clinically expect the programs will into clinic half in in and in clinic course be
look about in XXXX. XX with partner turn will to we tell you is a our Now, actively team to would XXXX. I incubated a This like with program that, in research project to Slide we to
got the year, to virus. As fit many two concerned time the we virus at QX areas we not about SARS-CoVX last discussions learn the on the of started to in and feature about
our from spike form ACEX and all domain constant combining SARS-CoVX avoid not FX-fusion developed the and extracellular its against using an an enzymatically virus. well molecule antibody-based introduced we extended considered a at and universal same used SARS-CoVX. unwanted we have immune for The active, well been drift the infect the efficiently could only tested patients likely product. established could decoy multiple vitro the And with ability candidate future What time, vaccine infection remain against of were a which challenge improve the benefit only not from acting is, vaccines. but human first generally neutralize more The known This be The where but and second, myeloma, the protein even risk as effectiveness focus general, the if can activation. variants, is to against has by [Technical the the patients to to therapeutic well for malignancies The pose limited mutational be molecule approaches drift, for the in not to undergo of this by viral half the Difficulty] virus SARS-CoVX. and We that may in cell to receptors cells. should domain wanted was coronaviruses as ACEX for inactive SARS-CoVX. mutated to domain as confer mutational who of an could receptor has IgG an outsmarted decoy of product was work virus our would on coronaviruses vivo approach been and as with to approaches, a B life for in the molecule FC
potential vitro tropic utility have to BXXX product of the this tested additionally, now We product African models’ SARS-CoVX, in, demonstrated efficacy type further the UK range vectors against to and candidate variants to viruses. press SARS-CoVX BXXXX suitor highlight South of in wider ability also the neutralize against the lentiviral the spike using a protein. we And ACEX of the
product lose ACEX obviously, active As against variants candidate SARS-CoVX you SARS-CoVX. against whereas all can effects see against therapeutic only SARS-CoVX, are whereas and inactive is variants, the neutralizes, activity SARS-CoVX antibodies the
universally a SARS-CoVX. neutralizing data and very opportunity again agent We’re to early encouraged develop potentially the this by
will XXXX With for fourth that, forward I Andrew the indicated, looking partner our Andrew? call program As over update. the to quarter for financial clinical to turn development. we're
